Abstract
Objectives Neutrophil elastase (NE) plays an important role in the development of acute respiratory distress syndrome (ARDS). Sivelestat sodium, as a selective NE inhibitor, may improve the outcomes of patients with sepsis-induced ARDS in previous studies, but there is a lack of solid evidence. This trial aimed to evaluate the effect of sivelestat sodium on oxygenation in patients with sepsis-induced ARDS.
Methods We conducted a multicenter, double-blind, randomized, placebo-controlled trial enrolling patients diagnosed with sepsis-induced ARDS admitted within 48 hours of the advent of symptoms. Patients were randomized in a 1:1 fashion to sivelestat or placebo. Trial drugs were administrated as a 24-hour continuous intravenous infusion for a minimum duration of 5 days and a maximum duration of 14 days. The primary outcome was PaO2/FiO2 ratio improvement on Day5 after randomization, defined by a greater than 50% improvement in PaO2/FiO2 compared with that on ICU admission or PaO2/FiO2 reached over 300 mmHg on Day5.
Results The study was stopped midway due to a potential between-group difference in mortality observed during the interim analysis. Overall, a total of 70 patients were randomized, of whom 34 were assigned to receive sivelastat sodium and 36 placebo. On day5, 19/34 (55.9%) patients in the sivelastat group had PaO2/FiO2 ratio improvement compared with 7/36 (19.4%) patients in the placebo group (risk difference, 0.36; 95% CI, 0.14 to 0.56, p<0.001). The Kaplan-Meier curves showed a significantly improved 28-day survival rate in patients receiving sivelestat than those not (hazard ratio, 0.32; 95% CI, 0.11 to 0.95; p=0.041).
Conclusion In patients with sepsis-induced ARDS, sivelestat sodium could improve oxygenation within the first five days and may be associated with decreased 28-day mortality.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
ChiCTR2200056892
Funding Statement
This study is supported by Shanghai Huilun (Jiangsu) Pharmaceutical Co., Ltd., which is also responsible for the supply of the study drug andplacebo as well as distribution to the participating centers. Funding agencyhad no input into the design, conduct, data collection, statistical analysis, orwriting of the manuscript.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
(1)Ethics committee/IRB of Liaocheng People's Hospital gave ethical approval for this work. (2)Ethics committee/IRB of Affiliated Hospital of Binzhou Medical College gave ethical approval for this work. (3)Ethics committee/IRB of Provincial Hospital of Shandong First Medical University gave ethical approval for this work. (4)Ethics committee/IRB of The First Affiliated Hospital of Shandong First Medical University gave ethical approval for this work. (5)Ethics committee/IRB of Linyi People's Hospital gave ethical approval for this work. (6)Ethics committee/IRB of Qilu Hospital of Shandong University gave ethical approval for this work. (7)Ethics committee/IRB of Shandong Public Health Clinical Centre gave ethical approval for this work. (8)Ethics committee/IRB of Tai'an Central Hospital gave ethical approval for this work. (9)Ethics committee/IRB of Qingdao Municipal Hospital gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present work are contained in the manuscript.
